

Special Issue

Epigenetic Modifications for Cancer Therapy

Message from the Guest Editor

Dear Colleagues, Cancer, a consequence of accumulative genetic mutations and epigenetic alterations, remains a formidable global human health threat due to its incurable nature. Over the past two decades, our understanding of mechanisms and roles of epigenetics in cancer initiation, progression, and metastasis has significantly expanded. Epigenetics, including DNA and RNA methylation, histone post-translational modifications, chromatin remodelers, and non-coding RNA regulation, play critical roles in many various cancer types by regulating the expression and activity of many oncogenes and tumor suppressors without DNA sequence alteration. Given the importance of epigenetic modifications in cancers, epigenetic therapy has become an attractive strategy. The Special Issue aims to focus on the latest advancements in the field of novel epigenetic therapies and epigenetic modifications for cancer, especially in metabolic reprogramming and the immune system. We invite submissions of original research articles, reviews, and perspectives on all relevant topics.

Guest Editor

Dr. Shasha Yin

Biochemistry & Molecular Biology Department, Medical University of South Carolina, Charleston, SC 29425, USA

Deadline for manuscript submissions

closed (25 May 2024)

G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



mdpi.com/si/190497

Genes
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
genes@mdpi.com

mdpi.com/journal/

[genes](https://genes.mdpi.com)



G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



About the Journal

Message from the Editor-in-Chief

Genes is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan
Department of Pathology, The University of Alabama at Birmingham,
1825 University Blvd, SHEL 814, Birmingham, AL 35294-2182, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))